Clinical Trials
14 trialsNCT05564377 2026-06-12
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04585958 2026-06-05
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03842228 2026-05-29
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05933265 2026-05-04
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Phase 1/2 Active not recruiting
NCT05898399 2026-05-01
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT04197713 2026-04-29
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03682289 2026-04-23
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT06201234 2025-12-01
ELEMENT
GBG Forschungs GmbH
Phase 2 Recruiting
NCT05900895 2025-11-20
PHOEBE
Dartmouth-Hitchcock Medical Center
Phase 1 Recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting